Botulinum toxin

Speaker 1...and this is particularly relevant when we consider pain treatments like botulinum toxin. It's often used for chronic conditions, such as migraine or myofascial pain, by blocking acetylcholine release.

Speaker 2Right, and the connection to aging and all-cause mortality here is fascinating. We know that chronic, unrelieved pain itself can accelerate biological aging. For instance, a study in *GeroScience* 2025 (PMID 39847262) found that painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening compared with painless neuropathy.

Speaker 1So, if botulinum toxin effectively relieves pain for certain individuals, it might indirectly mitigate some of those age-accelerating effects. It’s a complex interplay.

Speaker 2Absolutely. But the direct evidence on botulinum toxin’s impact on *biological aging* or *all-cause mortality* in humans is largely unestablished. While it’s a valuable tool for pain management, we don't have large-scale, long-term studies definitively showing it extends lifespan or reverses epigenetic aging markers.

Speaker 1Precisely. The focus of the research has been on efficacy and safety for the pain condition itself. When we talk about potential serious long-term harms like falls, sedation, or cognitive issues – those are more commonly associated with other pain medications, not typically botulinum toxin when used appropriately.

Speaker 2It’s crucial to distinguish. Legitimate, appropriate, supervised use of botulinum toxin helps many individuals manage debilitating pain. The question of its direct influence on all-cause mortality or biological aging is still an open area of research, not something currently established by evidence for or against.